pCPA Monthly Trends & Insights – July 31, 2018

August 13, 2018
-

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The July 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:

  • 9 negotiations were completed, while none were closed for a total of 228 completed/closed negotiations;
  • 8 new drug products have initiated pCPA negotiations, for a total of 46 active negotiations;
  • No new drug products were added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.

Negotiation Initiation

  • 8 new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
Brand Name Generic Name Manufacturer Indication Recommendation/
Notification to Implement Date
Time to Initiation*
Actemra Tocilizumab Hoffman-La Roche Limited Giant cell arteritis (GCA) March 27, 2018 110 days
Bavencio Avelumab EMD Serono – Pfizer Alliance Metastatic Merkel Cell Carcinoma April 6, 2018 100 days
Lartruvo Olaratumab Eli Lilly Canada Inc. Advanced soft tissue sarcoma (STS) May 3, 2018 73 days
Lixiana edoxaban Daiichi Sankyo, Inc Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism March 21, 2017 481 days
Lixiana edoxaban Daiichi Sankyo, Inc venous thromboembolism, treatment and recurrence prevention May 25, 2017 416 days
Ocrevus ocrelizumab Hoffman-La Roche Limited Multiple Sclerosis, relapsing November 21, 2017 236 days
Ocrevus ocrelizumab Hoffman-La Roche Limited Primary progressive multiple sclerosis April 26, 2018 80 days
Tecentriq atezolizumab Hoffman-La Roche Limited Non-small cell lung cancer July 6, 2018 9 days

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

For the second consecutive month, the pCPA has initiated 8 negotiations. All the files initiated in July are for new drugs or indications, associated with HTA recommendations that had not yet been actioned by the pCPA. This is the first month since January 2018 that no “pCPA-initiated” files or re-negotiations have been initiated. While the Lixiana indications have been under pCPA consideration for well over a year, negotiations for Tecentriq were initiated in the same month in which the HTA recommendation was issued.

Negotiatons Completed/Closed

  • 9 negotiations were completed since the last update, for a total of 202 completed negotiations.
Brand Name Generic Name Manufacturer Indication Negotiation Initiation Duration *
Dysport Therapeutic Abobotulinumtoxin A IPSEN Biopharmaceuticals Canada, Inc. Cervical dystonia May 2018 61 days
Dysport Therapeutic Abobotulinumtoxin A IPSEN Biopharmaceuticals Canada, Inc. Upper limb spasticity May, 2018 61 days
Hemangiol Propranolol Pierre Fabre Dermo-Cosmétique Infantile hemangioma August, 2017 334 days
Pomalyst** Pomalidomide Celgene Inc. Multiple Myeloma March, 2018 122 days
Procysbi Cysteamine bitartrate Horizon Therapeutics Canada Nephropathic cystinosis February, 2018 150 days
Renflexis Infliximab Merck Canada Inc. Inflammatory Conditions April, 2018 91 days
Rydapt Midostaurin Novartis Pharmaceuticals Canada Inc. Acute myeloid leukemia February, 2018 150 days
Tagrisso Osimertinib Astra Zeneca Canada Inc locally advanced or metastatic EGFR T790M mutationpositive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy September, 2017 303 days
Tresiba Insulin degludec Novo Nordisk Canada Inc. Type 1 and Type 2 diabetes April, 2018 91 days

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

** 2nd letter of intent, the first was completed in January 2015

 

  • No negotiations were closed since the last update, for a total of 26 closed negotiations.

Signals Decoded:

Of note, July saw the pCPA complete negotiations on the second infliximab biosimilar (Renflexis) as well as the first addition to the “long-acting insulin” category since the completion of the Basaglar (insulin glargine biosimilar) negotiation.

Files Under pCPA Consideration

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

  • Four new drug products received a CDEC or pERC recommendation or notification to implement in June 2018, for a total of approximately 26 products under pCPA Consideration.
Brand Name Generic Name Manufacturer Indication Final Recommendation/
Notification to Implement
Besponsa Inotuzumab ozogamicin Pfizer Canada Inc. Leukemia Acute Lymphoblastic Leukemia (ALL) Reimburse conditional on cost-effectiveness being improved to an acceptable level
Lonsurf Trifluridine and tipiracil Taiho Pharma Canada Inc. Metastatic Colorectal Cancer Does not recommend reimbursement
Symtuza Darunavir/cobicistat/

emtricitabine/tenofovir alafenamide

Janssen Inc. HIV 1 Infection Reimburse with clinical criteria and/or conditions
Tecentriq Atezolizumab Hoffman-La Roche Limited Non-small cell lung cancer Reimburse conditional on cost-effectiveness being improved and that the drug plan cost should not exceed the public drug plan cost of treatment with the least costly alternative immunotherapy

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share